At the end of the year, a number of pharmaceutical companies began to sell assets, and they were full of desire to survive

[pharmaceutical network industry trends] by the end of the year, some pharmaceutical companies are busy summarizing, some are busy planning for the future, and some are busy selling assets According to incomplete statistics, since December, a number of listed companies have released the news of asset sales It is pointed out in the industry that the main reasons for a company to dispose of its assets are generally to activate its assets, supplement its working capital, make strategic transformation and optimize its resource allocation If a pharmaceutical enterprise sells its assets for the purpose of activating its assets, it can be seen that these enterprises are full of "survival desire" On December 14, Sihuan biology disclosed the announcement on the sale of assets by wholly-owned subsidiaries that Guangxi intercontinental, a wholly-owned subsidiary, transferred its contracted forest trees and corresponding forest land use rights in Babu District, Bama County, Beiliu City and other places to 60000 forest farms with the transfer price of 170.65 million yuan Sihuan biology said that after the completion of this transaction, it will generate about 40 million earnings, which is subject to the company's audit report Sihuan biology explained in the announcement that the sale of forest assets is to activate the stock assets, improve the efficiency of asset operation, improve the financial situation of the company After the transaction is completed, it can reduce the proportion of the company's inventory, supplement the company's cash flow, meet the needs of the company's overall development strategy, and have a positive impact on the company's production and operation Data shows that Sihuan biology is a high-tech enterprise engaged in research, pilot test, production and sales of genetically engineered drugs and diagnostic reagents, integrating science, industry and trade According to the performance report, Sihuan biology achieved a revenue of 112 million yuan in the third quarter, an increase of 11.24%; and a net profit of 18.852 million yuan, an increase of 280.91% year on year On the evening of December 13, fosci pharmaceutical announced that the company plans to transfer the land located at No 2, Daijiazhuang, Anning District, Lanzhou and south side of Zhonghai square, Mogao Avenue, Anning District, Lanzhou to fosci group, the controlling shareholder, at a price of 103 million yuan The transfer of land use right is conducive to invigorating the company's stock assets, promoting the company to focus on the main pharmaceutical industry, reducing the company's capital pressure, financing costs and tax related risks, said foci pharmaceutical If the transaction is successfully completed, it is expected to increase the total profit of foci pharmaceutical in the later stage by about 78.586 million yuan According to the data, the main business of foci pharmaceutical is the R & D, manufacturing and sales of Chinese patent medicine and big health products, as well as the cultivation, processing and sales of Chinese herbal medicines According to the financial report, in the first three quarters of 2019, foci pharmaceutical achieved an operating revenue of 468 million yuan, a year-on-year increase of 15.53%; and a net profit of 72.9866 million yuan, a year-on-year increase of 27.63% Haizheng pharmaceutical announced on December 10 that it would withdraw 1.317 billion yuan of various assets depreciation reserves and reduce the company's net profit this year accordingly According to the financial report, the net profit of Haizheng pharmaceutical in the first three quarters of this year was 1.255 billion yuan For Haizheng pharmaceutical, which has lost four years in a row, it doesn't seem optimistic It is worth mentioning that since the separation from Pfizer in 2015, Haizheng pharmaceutical industry has lost non net profit for four consecutive years Under the pressure of performance, Haizheng pharmaceutical began to sell assets Since this year, Haizheng pharmaceutical has frequently sold its assets Haizheng pharmaceutical said it had publicly listed properties in Beijing, Shanghai and other four places in order to activate idle assets Through the introduction of social capital, Haizheng Bray, a subsidiary of the company, has increased capital and shares and transferred some old shares in order to improve the efficiency of asset operation According to the data, Haizheng pharmaceutical is a production base of antibiotics and anti-tumor drugs Its main business includes API business, domestic preparation business, biological medicine business and pharmaceutical business.